找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪(fǎng)問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Lebensqualit?t im Alter; Generationenbeziehun Andreas Motel-Klingebiel (Dr.),Hans-Joachim Kondra Book 2002 Springer Fachmedien Wiesbaden 20

[復(fù)制鏈接]
31#
發(fā)表于 2025-3-26 23:03:00 | 只看該作者
32#
發(fā)表于 2025-3-27 03:23:41 | 只看該作者
r the use in parasitology (He?mánek and Prokopi? 1989). In this study we investigated the possibility of thymic preparations to influence the resistance to model parasite infections (2 helminthoses — cysticercosis and ascaridosis and 2 protozooses — coccidiosis and cryptosporidiosis) in intact and i
33#
發(fā)表于 2025-3-27 07:59:59 | 只看該作者
34#
發(fā)表于 2025-3-27 12:38:34 | 只看該作者
Betina Hollsteintoxic side effects (Schumann and others, 1989). Reduction of toxicity may be accomplished by encapsulation of MTPPE in liposomes, which are taken up preferably by the cells of the MPS. The question is whether liposome-encapsulated MTPPE (LE-MTPPE) retains its activity. LE-MTPPE has proven to be bene
35#
發(fā)表于 2025-3-27 16:16:28 | 只看該作者
Jan Marbachsing nodal regions that may not be irradiated with more conformal techniques. Traditional forms of radiation in particular pose challenges for combination trials with immunotherapy. This chapter explores these issues in more detail and provides insights as to how radiation therapy can be optimized t
36#
發(fā)表于 2025-3-27 18:04:11 | 只看該作者
Frank Lettke auditory complications can lead to speech recognition deficits and sensorineural hearing loss. Ocular toxicities are among the most common adverse events resulting from the use of these agents. The majority of ocular immune-related adverse events (irAEs) are mild, low-grade, non-sight threatening,
37#
發(fā)表于 2025-3-28 01:25:04 | 只看該作者
38#
發(fā)表于 2025-3-28 02:46:10 | 只看該作者
39#
發(fā)表于 2025-3-28 08:14:48 | 只看該作者
Heinz Blaumeiser,Thomas Klie development to predict response to immunotherapy and risk of toxicity. This book chapter is a comprehensive review of immunotherapeutic approaches, both approved and investigational, for the treatment of renal cell carcinoma, urothelial carcinoma, and prostate cancer.
40#
發(fā)表于 2025-3-28 11:37:24 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 21:07
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
门源| 保亭| 云和县| 子洲县| 樟树市| 息烽县| 陇西县| 同德县| 大埔县| 大荔县| 蓬安县| 华宁县| 九寨沟县| 寿阳县| 精河县| 邹平县| 朝阳市| 博白县| 锦屏县| 洛宁县| 饶河县| 舟山市| 浦县| 新乡市| 抚顺市| 东安县| 老河口市| 岫岩| 天柱县| 衡水市| 华安县| 鲜城| 西充县| 建瓯市| 尼木县| 浠水县| 新乡市| 襄樊市| 左权县| 喀喇沁旗| 梅河口市|